| Gastro-intestinal system | |||||
|---|---|---|---|---|---|
| Gastro-intestinal system / Inflammatory bowel disease | |||||
| adalimumab | Hospital only |
NICE TA187 NICE TA329 NICE TA199 NICE TA195 NICE TA375 NICE TA715 NICE TA383 NICE TA392 NICE TA146 NICE TA460 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| Solution for injection | |||||
| Adalimumab (Non-proprietary) | |||||
| Amgevita (Amgen Ltd) | |||||
| Humira (AbbVie Ltd) | Hospital only | ||||
|
ADALIMUMAB
Dose escalation of Adalimumab is approved for Crohn's disease and ulcerative colitis |
|||||
| Hyrimoz (Sandoz Ltd) | |||||
| Idacio (Fresenius Kabi Ltd) | |||||
| Imraldi (Biogen Idec Ltd) | |||||
| Yuflyma (Celltrion Healthcare UK Ltd) | |||||
| azathioprine | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral suspension | |||||
| Jayempi (Nova Laboratories Ltd) | |||||
| Oral tablet | |||||
| Azathioprine (Non-proprietary) | |||||
| Imuran (Aspen Pharma Trading Ltd) | |||||
| balsalazide sodium | Specialist knowledge/initiation | ||||
| Oral capsule | |||||
| Colazide (Almirall Ltd) | |||||
| beclometasone dipropionate | Hospital only | ||||
|
Us of beclometasone modified release tablets
Oral beclometasone modified release tablets should only be used as second-line option (after prednisolone tablets) for the treatment of mild or moderate ulcerative colitis in active phase of left-sided or extensive UC. This would be used as add-on therapy to 5-ASA containing drugs in patients who are non-responders to 5-ASA therapy. The full 4 week therapy cycle must be prescribed by secondary care. |
|||||
| Modified-release tablet | |||||
| Clipper (Chiesi Ltd) | Hospital only | ||||
|
Us of beclometasone modified release tablets
Oral beclometasone modified release tablets should only be used as second-line option (after prednisolone tablets) for the treatment of mild or moderate ulcerative colitis in active phase of left-sided or extensive UC. This would be used as add-on therapy to 5-ASA containing drugs in patients who are non-responders to 5-ASA therapy. The full 4 week therapy cycle must be prescribed by secondary care. |
|||||
| Pressurised inhalation | |||||
| Beclu (Lupin Healthcare (UK) Ltd) | |||||
| Clenil Modulite (Chiesi Ltd) | |||||
| Kelhale (Cipla EU Ltd) | |||||
| Qvar (Teva UK Ltd) | |||||
| Qvar Autohaler (Teva UK Ltd) | |||||
| Qvar Easi-Breathe (Teva UK Ltd) | |||||
| Soprobec (Glenmark Pharmaceuticals Europe Ltd) | |||||
| Inhalation powder | |||||
| Easyhaler (Orion Pharma (UK) Ltd) | |||||
| Spray | |||||
| Beclometasone dipropionate (Non-proprietary) | |||||
| Beconase (GlaxoSmithKline UK Ltd, Omega Pharma Ltd) | |||||
| Nasobec (Teva UK Ltd) | |||||
| Cutaneous ointment | |||||
| Beclometasone dipropionate (Non-proprietary) | |||||
| Cutaneous cream | |||||
| Beclometasone dipropionate (Non-proprietary) | |||||
| budesonide | Specialist knowledge/initiation |
NICE TA708 NICE TA937 |
|||
|
JPG decision
October 2019 - The Joint Prescribing Group approved the use of Jorveza (orodispersible budesonide) for the treatment of eosinophilic oesophagitis.
NICE also published a TA in June 2021 and recommended the use of budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis. |
|||||
| Orodispersible tablet | |||||
| Jorveza (Dr. Falk Pharma UK Ltd) | |||||
|
JPG decision
October 2019 - The Joint Prescribing Group approved the use of Jorveza (orodispersible budesonide) for the treatment of eosinophilic oesophagitis.
NICE also published a TA in June 2021 and recommended the use of budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis. |
|||||
| Modified-release tablet | |||||
| Cortiment (Ferring Pharmaceuticals Ltd) | Specialist knowledge/initiation | ||||
| Modified-release capsule | |||||
| Budesonide (Non-proprietary) | |||||
| Kinpeygo (Genus Pharmaceuticals Holdings Ltd) | |||||
| Gastro-resistant capsule | |||||
| Budenofalk (Dr. Falk Pharma UK Ltd) | Specialist knowledge/initiation | ||||
| Gastro-resistant granules | |||||
| Budenofalk (Dr. Falk Pharma UK Ltd) | Specialist knowledge/initiation | ||||
| Inhalation powder | |||||
| Budelin Novolizer (Viatris UK Healthcare Ltd) | |||||
| Easyhaler (Orion Pharma (UK) Ltd) | |||||
| Pulmicort Turbohaler (AstraZeneca UK Ltd) | |||||
| Nebuliser liquid | |||||
| Budesonide (Non-proprietary) | |||||
| Pulmicort Respules (AstraZeneca UK Ltd) | |||||
| Enema | |||||
| Entocort (Tillotts Pharma UK Ltd) | |||||
| Spray | |||||
| Budesonide (Non-proprietary) | |||||
| Rectal foam | |||||
| Budenofalk (Dr. Falk Pharma UK Ltd) | |||||
| ciclosporin | Shared care guideline |
NICE TA369 |
|||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral solution | |||||
| Neoral (Novartis Pharmaceuticals UK Ltd) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Sandimmun (Novartis Pharmaceuticals UK Ltd) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Solution for infusion | |||||
| Sandimmun (Novartis Pharmaceuticals UK Ltd) | Hospital only | ||||
| Eye drops | |||||
| Ikervis (Santen UK Ltd) | |||||
| Verkazia (Santen UK Ltd) | |||||
| Oral capsule | |||||
| Ciclosporin (Non-proprietary) | |||||
| Capimune (Viatris UK Healthcare Ltd) | |||||
| Capsorin (Morningside Healthcare Ltd) | |||||
| Deximune (Dexcel-Pharma Ltd) | |||||
| Neoral (Novartis Pharmaceuticals UK Ltd) | |||||
| Sandimmun (Novartis Pharmaceuticals UK Ltd) | |||||
| Vanquoral (Teva UK Ltd) | |||||
| etrasimod |
NICE TA956 |
||||
| Oral tablet | |||||
| Etrasimod (Non-proprietary) | |||||
| filgotinib | Hospital only |
NICE TA676 NICE TA792 |
|||
| Oral tablet | |||||
| Jyseleca (Galapagos Biotech Ltd) | Hospital only | ||||
| golimumab | Hospital only |
NICE TA220 NICE TA375 NICE TA225 NICE TA383 NICE TA497 NICE TA329 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| Solution for injection | |||||
| Simponi (Merck Sharp & Dohme (UK) Ltd) | Hospital only | ||||
|
GOLIMUMAB
The JPG agreed to approve this medicine for use at Homerton University Hospital, Foundation Trust provided it is used in accordance with the relevant NICE TA(s). |
|||||
| hydrocortisone | Specialist knowledge/initiation | ||||
| Soluble tablet | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Muco-adhesive buccal tablet | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Modified-release tablet | |||||
| Plenadren (Takeda UK Ltd) | |||||
| Modified-release capsule | |||||
| Efmody (Diurnal Ltd) | |||||
| Oral solution | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Solution for injection | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Powder for solution for injection | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Solu-Cortef (Pfizer Ltd) | |||||
| Powder and solvent for solution for injection | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Solu-Cortef (Pfizer Ltd) | |||||
| Eye drops | |||||
| Softacort (Thea Pharmaceuticals Ltd) | |||||
| Oral tablet | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Hydventia (OcXia) | |||||
| Cutaneous ointment | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Oral granules | |||||
| Alkindi (Diurnal Ltd) | |||||
| Cutaneous cream | |||||
| Hydrocortisone (Non-proprietary) | |||||
| Dermacort (Marlborough Pharmaceuticals Ltd) | |||||
| Hc45 (Karo Healthcare UK Ltd) | |||||
| infliximab | Hospital only |
NICE TA134 NICE TA195 NICE TA375 NICE TA715 NICE TA199 NICE TA187 NICE TA163 NICE TA329 NICE TA383 |
|||
|
Biosimilar
Remsima® (biosimilar infliximab) is the formulary choice brand for infliximab. |
|||||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| Solution for injection | |||||
| Remsima (Celltrion Healthcare UK Ltd) | Hospital only | ||||
| Powder for solution for infusion | |||||
| Flixabi (Biogen Idec Ltd) | |||||
| Inflectra (Pfizer Ltd) | |||||
| Remicade (Merck Sharp & Dohme (UK) Ltd) | |||||
| Remsima (Celltrion Healthcare UK Ltd) | |||||
| Zessly (Sandoz Ltd) | |||||
| mercaptopurine | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral suspension | |||||
| Xaluprine (Nova Laboratories Ltd) | |||||
| Oral tablet | |||||
| Mercaptopurine (Non-proprietary) | |||||
| Hanixol (Fontus Health Ltd) | |||||
| mesalazine | Specialist knowledge/initiation | ||||
|
Preferred brand of 400mg and 800mg mesalazine gastro-resistant tablets
Jan 2023 - The North East London Formulary & Pathways Group (FPG) approved Octasa® as the preferred cost-effective 400mg and 800mg mesalazine gastro-resistant tablets for use in North East London.
|
|||||
| Modified-release tablet | |||||
| Mezavant XL (Takeda UK Ltd) | Specialist knowledge/initiation | ||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Pentasa (Ferring Pharmaceuticals Ltd) | Specialist knowledge/initiation | ||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Gastro-resistant tablet | |||||
| Mesalazine (Non-proprietary) | |||||
| Asacol (AbbVie Ltd) | |||||
| Octasa MR (Tillotts Pharma UK Ltd) | Specialist knowledge/initiation | ||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Salcrozine (Galen Ltd) | |||||
| Salofalk (Dr. Falk Pharma UK Ltd) | Specialist knowledge/initiation | ||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Zintasa (Morningside Healthcare Ltd) | |||||
| Modified-release granules | |||||
| Pentasa (Ferring Pharmaceuticals Ltd) | Specialist knowledge/initiation | ||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Salofalk (Dr. Falk Pharma UK Ltd) | Specialist knowledge/initiation | ||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Suppository | |||||
| Octasa (Tillotts Pharma UK Ltd) | |||||
| Pentasa (Ferring Pharmaceuticals Ltd) | Specialist knowledge/initiation | ||||
| Salofalk (Dr. Falk Pharma UK Ltd) | Specialist knowledge/initiation | ||||
| Enema | |||||
| Pentasa (Ferring Pharmaceuticals Ltd) | |||||
| Salofalk (Dr. Falk Pharma UK Ltd) | |||||
| Rectal foam | |||||
| Salofalk (Dr. Falk Pharma UK Ltd) | |||||
| methotrexate | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral solution | |||||
| Methotrexate (Non-proprietary) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Jylamvo (Esteve Pharmaceuticals Ltd) | |||||
| Solution for injection | |||||
| Methotrexate (Non-proprietary) | Hospital only | ||||
| Methofill (Accord-UK Ltd) | |||||
| Metoject PEN (medac UK) | Hospital only | ||||
| Nordimet (Nordic Pharma Ltd) | Hospital only | ||||
| Zlatal (Nordic Pharma Ltd) | Hospital only | ||||
| Solution for infusion | |||||
| Methotrexate (Non-proprietary) | Hospital only | ||||
| Oral tablet | |||||
| Methotrexate (Non-proprietary) | |||||
| Maxtrex (Pfizer Ltd) | |||||
| methylprednisolone | |||||
| Powder and solvent for solution for injection | |||||
| Methylprednisolone (Non-proprietary) | |||||
| Solu-Medrone (Pfizer Ltd) | |||||
| Suspension for injection | |||||
| Depo-Medrone (Pfizer Ltd) | |||||
| Oral tablet | |||||
| Medrone (Pfizer Ltd) | |||||
| mirikizumab | Hospital only |
NICE TA925 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| Solution for injection | |||||
| Omvoh (Eli Lilly and Company Ltd) | Hospital only | ||||
| Solution for infusion | |||||
| Omvoh (Eli Lilly and Company Ltd) | Hospital only | ||||
| olsalazine sodium | Hospital only | ||||
| Oral tablet | |||||
| Olsalazine sodium (Non-proprietary) | |||||
| Oral capsule | |||||
| Olsalazine sodium (Non-proprietary) | |||||
| ozanimod | Hospital only |
NICE TA706 NICE TA828 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| Oral capsule | |||||
| Zeposia (Bristol-Myers Squibb Pharmaceuticals Ltd) | Hospital only | ||||
| prednisolone | Joint formulary choice | ||||
| Soluble tablet | |||||
| Prednisolone (Non-proprietary) | |||||
| Gastro-resistant tablet | |||||
| Prednisolone (Non-proprietary) | Not approved for prescribing | ||||
| Dilacort (Crescent Pharma Ltd) | Not approved for prescribing | ||||
| Oral solution | |||||
| Prednisolone (Non-proprietary) | Joint formulary choice | ||||
| Ear/eye drops solution | |||||
| Prednisolone (Non-proprietary) | |||||
| Eye drops | |||||
| Prednisolone (Non-proprietary) | |||||
| Pred Forte (AbbVie Ltd) | |||||
| Suppository | |||||
| Prednisolone (Non-proprietary) | Joint formulary choice | ||||
| Enema | |||||
| Prednisolone (Non-proprietary) | |||||
| Oral tablet | |||||
| Prednisolone (Non-proprietary) | |||||
| Rectal foam | |||||
| Prednisolone (Non-proprietary) | |||||
| risankizumab | Hospital only |
NICE TA596 NICE TA803 NICE TA888 |
|||
| Solution for injection | |||||
| Skyrizi (AbbVie Ltd) | |||||
| Solution for infusion | |||||
| Skyrizi (AbbVie Ltd) | Hospital only | ||||
| sulfasalazine | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Gastro-resistant tablet | |||||
| Sulfasalazine (Non-proprietary) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Salazopyrin EN (Pfizer Ltd) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral suspension | |||||
| Sulfasalazine (Non-proprietary) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Suppository | |||||
| Salazopyrin (Pfizer Ltd) | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral tablet | |||||
| Sulfasalazine (Non-proprietary) | |||||
| Salazopyrin (Pfizer Ltd) | |||||
| tofacitinib | Hospital only |
NICE TA480 NICE TA543 NICE TA920 NICE TA547 |
|||
| Modified-release tablet | |||||
| Xeljanz (Pfizer Ltd) | Hospital only | ||||
| Oral tablet | |||||
| Xeljanz (Pfizer Ltd) | Hospital only | ||||
| upadacitinib | Hospital only |
NICE TA665 NICE TA744 NICE TA768 NICE TA829 NICE TA861 NICE TA814 NICE TA856 NICE TA905 |
|||
|
North East London Formulary & Pathways Group’s Decision - Upadacitinib for Crohn's disease
April 2023 - The North East London Formulary & Pathways Group (FPG) approved the use of Upadicitinib for the treatment of Crohn's disease under a Free of Charge Scheme. This indication is currently under review by NICE - FPG decision will be reviewed upon publication of the NICE Technology Appraisal. |
|||||
| Modified-release tablet | |||||
| Rinvoq (AbbVie Ltd) | Hospital only | ||||
| ustekinumab | Hospital only |
NICE TA180 NICE TA340 NICE TA456 NICE TA633 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| Solution for injection | |||||
| Stelara (Janssen-Cilag Ltd) | Hospital only | ||||
| Solution for infusion | |||||
| Stelara (Janssen-Cilag Ltd) | Hospital only | ||||
| vedolizumab | Hospital only |
NICE TA352 NICE TA342 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
|
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine
This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use. |
|||||
| Solution for injection | |||||
| Entyvio (Takeda UK Ltd) | Hospital only | ||||
| Powder for solution for infusion | |||||
| Entyvio (Takeda UK Ltd) | Hospital only | ||||
| Gastro-intestinal system / Irritable bowel syndrome | |||||
| alverine citrate | Joint formulary choice | ||||
| Oral capsule | |||||
| Alverine citrate (Non-proprietary) | |||||
| Audmonal (Teva UK Ltd) | |||||
| Spasmonal (Viatris UK Healthcare Ltd) | |||||
| alverine with simeticone | |||||
| Oral capsule | |||||
| SimAlvia (Mayoly UK Ltd) | |||||
| linaclotide | Joint formulary choice | ||||
| Oral capsule | |||||
| Constella (AbbVie Ltd) | |||||
| mebeverine hydrochloride | Joint formulary choice | ||||
|
Mebeverine Hydrochloride
Mebeverine oral suspension has NOT been approved for prescribing. |
|||||
| Modified-release capsule | |||||
| Mebeverine hydrochloride (Non-proprietary) | Joint formulary choice | ||||
| Aurobeverine MR (Milpharm Ltd) | Joint formulary choice | ||||
| Colofac MR (Viatris UK Healthcare Ltd) | Joint formulary choice | ||||
| Oral suspension | |||||
| Mebeverine hydrochloride (Non-proprietary) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Mebeverine hydrochloride (Non-proprietary) | |||||
| Colofac (Viatris UK Healthcare Ltd) | |||||
| mebeverine with ispaghula husk | Not approved for prescribing | ||||
| Effervescent granules | |||||
| Fybogel Mebeverine (Reckitt Benckiser Healthcare (UK) Ltd) | Not approved for prescribing | ||||
| peppermint oil | Joint formulary choice | ||||
| Modified-release capsule | |||||
| Colpermin (Johnson & Johnson Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Peppermint oil (Non-proprietary) | Joint formulary choice | ||||
| Buscomint (Sanofi Consumer Healthcare) | |||||
| ColoPep (TriOn Pharma Ltd) | |||||
| Colomint (Ambe Ltd) | Joint formulary choice | ||||
| Mintec (Teofarma S.r.l.) | Joint formulary choice | ||||
| PepperMinn (Essential-Healthcare Ltd) | Joint formulary choice | ||||
| Gastro-intestinal system / Short bowel syndrome | |||||
| cimetidine | Not approved for prescribing | ||||
| Oral solution | |||||
| Cimetidine (Non-proprietary) | Not approved for prescribing | ||||
| Tagamet (Rosemont Pharmaceuticals Ltd) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Cimetidine (Non-proprietary) | |||||
| teduglutide | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA804 |
|||
|
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine
This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use. |
|||||
| Powder and solvent for solution for injection | |||||
| Revestive (Takeda UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Gastro-intestinal system / Food allergy | |||||
| chlorphenamine maleate | Joint formulary choice | ||||
| Oral solution | |||||
| Chlorphenamine maleate (Non-proprietary) | Joint formulary choice | ||||
| Allerief (Crescent Pharma Ltd) | Joint formulary choice | ||||
| Piriton (Haleon UK Ltd) | Joint formulary choice | ||||
| Solution for injection | |||||
| Chlorphenamine maleate (Non-proprietary) | Hospital only | ||||
| Oral tablet | |||||
| Chlorphenamine maleate (Non-proprietary) | Joint formulary choice | ||||
| Allerief (Crescent Pharma Ltd) | |||||
| Hayleve (Genesis Pharmaceuticals Ltd) | |||||
| Piriton (Haleon UK Ltd) | |||||
| sodium cromoglicate | Not approved for prescribing | ||||
| Oral solution | |||||
| Sodium cromoglicate (Non-proprietary) | |||||
| Eye drops | |||||
| Sodium cromoglicate (Non-proprietary) | |||||
| Catacrom (Rayner Pharmaceuticals Ltd) | |||||
| Eycrom (Aspire Pharma Ltd) | |||||
| Opticrom (Thornton & Ross Ltd) | |||||
| Oral capsule | |||||
| Sodium cromoglicate (Non-proprietary) | |||||
| Gastro-intestinal system / Rectal and anal disorders | |||||
| diltiazem hydrochloride | |||||
|
Brand prescribing recommended
Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:
Please prescribe this product by brand. |
|||||
| Modified-release tablet | |||||
| Diltiazem hydrochloride (Non-proprietary) | |||||
| Retalzem (Kent Pharma (UK) Ltd) | |||||
| Tildiem (Sanofi) | |||||
| Tildiem Retard (Sanofi) | |||||
| Zeyam (Ennogen Pharma Ltd) | |||||
| Modified-release capsule | |||||
| Adizem-SR (Napp Pharmaceuticals Ltd) | |||||
| Adizem-XL (Napp Pharmaceuticals Ltd) | |||||
| Angitil SR (Ethypharm UK Ltd) | |||||
| Angitil XL (Ethypharm UK Ltd) | |||||
| Slozem (Zentiva Pharma UK Ltd) | |||||
| Tildiem LA (Sanofi) | |||||
| Viazem XL (Thornton & Ross Ltd) | |||||
| Zemtard XL (Galen Ltd) | |||||
| Gastro-intestinal system / Anal fissures | |||||
| glyceryl trinitrate | Joint formulary choice | ||||
| Sublingual tablet | |||||
| Glyceryl trinitrate (Non-proprietary) | |||||
| Sublingual spray | |||||
| Glyceryl trinitrate (Non-proprietary) | |||||
| Nitrolingual (Beaumont Pharma Ltd) | |||||
| Solution for infusion | |||||
| Glyceryl trinitrate (Non-proprietary) | |||||
| Nitronal (Beaumont Pharma Ltd) | |||||
| Transdermal patch | |||||
| Deponit (Forum Health Products Ltd) | |||||
| Minitran (Viatris UK Healthcare Ltd) | |||||
| Rectal ointment | |||||
| Rectogesic (Kyowa Kirin International UK NewCo Ltd) | Joint formulary choice | ||||
| lidocaine hydrochloride | Not approved for prescribing | ||||
| Solution for injection | |||||
| Lidocaine hydrochloride (Non-proprietary) | |||||
| Ointment | |||||
| Lidocaine hydrochloride (Non-proprietary) | |||||
| Spray | |||||
| Stud 100 (Pound International Ltd) | |||||
| Xylocaine (Aspen Pharma Trading Ltd) | |||||
| Medicated plaster | |||||
| Ralvo (Grunenthal Ltd) | |||||
| Versatis (Grunenthal Ltd) | |||||
| Cutaneous cream | |||||
| LMX 4 (Ferndale Pharmaceuticals Ltd) | |||||
| Vagisil medicated (Combe International Ltd) | |||||
| Gastro-intestinal system / Haemorrhoids | |||||
| benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide | Joint formulary choice | ||||
| Suppository | |||||
| Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide (Non-proprietary) | Joint formulary choice | ||||
| Rectal ointment | |||||
| Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide (Non-proprietary) | |||||
| cinchocaine with hydrocortisone | Joint formulary choice | ||||
| Suppository | |||||
| Proctosedyl (Phoenix Labs Ltd) | Joint formulary choice | ||||
| Uniroid HC (Essential Generics Ltd) | Joint formulary choice | ||||
| Rectal ointment | |||||
| Proctosedyl (Phoenix Labs Ltd) | |||||
| Uniroid HC (Essential Generics Ltd) | |||||
| cinchocaine with prednisolone | Not approved for prescribing | ||||
| Suppository | |||||
| Scheriproct (Karo Healthcare UK Ltd) | Not approved for prescribing | ||||
| Rectal ointment | |||||
| Scheriproct (Karo Healthcare UK Ltd) | |||||
| hydrocortisone with lidocaine | Joint formulary choice | ||||
| Cutaneous ointment | |||||
| Xyloproct (Aspen Pharma Trading Ltd) | |||||
| phenol | Not approved for prescribing | ||||
| Solution for injection | |||||
| Phenol (Non-proprietary) | Not approved for prescribing | ||||
| Gastro-intestinal system / Bowel cleansing | |||||
| bisacodyl | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Bisacodyl (Non-proprietary) | Joint formulary choice | ||||
| Dulco-Lax (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
| Suppository | |||||
| Dulco-Lax (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
| citric acid with magnesium carbonate | |||||
| Effervescent powder | |||||
| Citramag (Cambridge Healthcare Supplies Ltd) | |||||
| docusate sodium | Joint formulary choice | ||||
| Oral solution | |||||
| Docusate sodium (Non-proprietary) | Joint formulary choice | ||||
| Docusol (Typharm Ltd) | Joint formulary choice | ||||
| Ear drops | |||||
| Molcer (Wallace Manufacturing Chemists Ltd) | |||||
| Waxsol (Viatris UK Healthcare Ltd) | |||||
| Enema | |||||
| Norgalax (Essential Pharma Ltd) | |||||
| Oral capsule | |||||
| Dioctyl (Teofarma S.r.l.) | |||||
| macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride | Hospital only | ||||
| Form unstated | |||||
| Moviprep (Forum Health Products Ltd) | Hospital only | ||||
| Plenvu (Forum Health Products Ltd) | Hospital only | ||||
| macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride | Hospital only | ||||
| magnesium citrate with sodium picosulfate | Hospital only | ||||
| Powder for oral solution | |||||
| CitraFleet (Recordati Pharmaceuticals Ltd) | |||||
| Picolax (Ferring Pharmaceuticals Ltd) | |||||
| magnesium sulfate | Not approved for prescribing | ||||
| Solution for injection | |||||
| Magnesium sulfate (Non-proprietary) | |||||
| Solution for infusion | |||||
| Magnesium sulfate (Non-proprietary) | |||||
| Powder | |||||
| Magnesium sulfate (Non-proprietary) | |||||
| Gastro-intestinal system / Constipation | |||||
| arachis oil | Hospital only | ||||
| Enema | |||||
| Arachis oil (Non-proprietary) | |||||
| bisacodyl | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Bisacodyl (Non-proprietary) | Joint formulary choice | ||||
| Dulco-Lax (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
| Suppository | |||||
| Dulco-Lax (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
| co-danthramer | Specialist knowledge/initiation | ||||
| Oral suspension | |||||
| Co-danthramer (Non-proprietary) | Specialist knowledge/initiation | ||||
| co-danthrusate | Not approved for prescribing | ||||
| Oral suspension | |||||
| Co-danthrusate (Non-proprietary) | Not approved for prescribing | ||||
| docusate sodium | Joint formulary choice | ||||
| Oral solution | |||||
| Docusate sodium (Non-proprietary) | Joint formulary choice | ||||
| Docusol (Typharm Ltd) | Joint formulary choice | ||||
| Ear drops | |||||
| Molcer (Wallace Manufacturing Chemists Ltd) | |||||
| Waxsol (Viatris UK Healthcare Ltd) | |||||
| Enema | |||||
| Norgalax (Essential Pharma Ltd) | |||||
| Oral capsule | |||||
| Dioctyl (Teofarma S.r.l.) | |||||
| glycerol | Joint formulary choice | ||||
| Suppository | |||||
| Glycerol (Non-proprietary) | Joint formulary choice | ||||
| ispaghula husk | Joint formulary choice | ||||
| Effervescent granules | |||||
| Ispaghula husk (Non-proprietary) | |||||
| Fybogel (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
| Fybogel Hi-Fibre (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
| Ispagel (Bristol Laboratories Ltd) | Joint formulary choice | ||||
| Granules for oral suspension | |||||
| Ispaghula husk (Non-proprietary) | |||||
| lactulose | Joint formulary choice | ||||
| Oral solution | |||||
| Lactulose (Non-proprietary) | Joint formulary choice | ||||
| liquid paraffin | Not approved for prescribing | ||||
| Oral liquid | |||||
| Liquid paraffin (Non-proprietary) | |||||
| macrogol 3350 | Joint formulary choice | ||||
| Powder for oral solution | |||||
| TransiSoft (Mayoly UK Ltd) | |||||
| macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride | Joint formulary choice | ||||
| Oral solution | |||||
| Movicol (Forum Health Products Ltd) | Joint formulary choice | ||||
| Powder for oral solution | |||||
| Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Non-proprietary) | |||||
| CosmoCol (Stirling Anglian Pharmaceuticals Ltd) | |||||
| Laxido (Galen Ltd) | |||||
| Molaxole (Viatris UK Healthcare Ltd) | |||||
| Movicol (Forum Health Products Ltd, Norgine Pharmaceuticals Ltd) | |||||
| Strigol (Strides Pharma UK Ltd) | |||||
| magnesium hydroxide | Not approved for prescribing | ||||
| Oral suspension | |||||
| Magnesium hydroxide (Non-proprietary) | Not approved for prescribing | ||||
| Phillips' Milk of Magnesia (Omega Pharma Ltd) | Not approved for prescribing | ||||
| methylnaltrexone bromide | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Solution for injection | |||||
| Relistor (Bausch & Lomb UK Ltd) | Not approved for prescribing | ||||
| naldemedine | Not approved for prescribing |
NICE TA651 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton University Hospital Foundation Trust does not provide the service
The Joint Prescribing Group (JPG) agreed not to approve this medicine for use at Homerton University Hospital Foundation Trust as the trust does not provide this service. The JPG recommends the funding of this medicine to enable it to be prescribed or initiated by other providers, provided it is used in accordance with the relevant NICE Technology Appraisal(s). |
|||||
| Oral tablet | |||||
| Rizmoic (Sandoz Ltd) | |||||
| naloxegol | Hospital only |
NICE TA345 |
|||
| Oral tablet | |||||
| Moventig (Kyowa Kirin International UK NewCo Ltd) | |||||
| prucalopride | Specialist knowledge/initiation |
NICE TA211 |
|||
| Oral tablet | |||||
| Prucalopride (Non-proprietary) | |||||
| Resolor (Takeda UK Ltd) | |||||
| senna | Joint formulary choice | ||||
| Oral solution | |||||
| Senokot (Reckitt Benckiser Healthcare (UK) Ltd) | Joint formulary choice | ||||
| Oral tablet | |||||
| Senna (Non-proprietary) | |||||
| Cenlax (Manx Healthcare Ltd) | |||||
| Senease Twelve Years Plus (RX Farma) | |||||
| Senokot (Reckitt Benckiser Healthcare (UK) Ltd) | Joint formulary choice | ||||
| senna with ispaghula husk | Not approved for prescribing | ||||
| Oral granules | |||||
| Manevac (Viatris UK Healthcare Ltd) | |||||
| sodium acid phosphate with sodium bicarbonate | |||||
| Suppository | |||||
| Lecicarbon A (Aspire Pharma Ltd) | |||||
| Lecicarbon C (Aspire Pharma Ltd) | |||||
| sodium acid phosphate with sodium phosphate | Specialist knowledge/initiation | ||||
|
Joint Prescribing Group's decision
The Joint Prescribing Group (JPG) agreed to approve the addition of Fleet Phospho-Soda® 24.4g/10.8g oral solution to the joint formulary as a booster bowel cleansing solution in patients undergoing Crohn's capsule endoscopy (July 2019) and colon capsule endoscopy for cancer screening (April 2021). Formulary status - Blue (hospital only) |
|||||
| Oral solution | |||||
| Fleet Phospho-soda (Recordati Pharmaceuticals Ltd) | Not approved for prescribing | ||||
|
Joint Prescribing Group's decision
The Joint Prescribing Group (JPG) agreed to approve the addition of Fleet Phospho-Soda® 24.4g/10.8g oral solution to the joint formulary as a booster bowel cleansing solution in patients undergoing Crohn's capsule endoscopy (July 2019) and colon capsule endoscopy for cancer screening (April 2021). Formulary status - Blue (hospital only) |
|||||
| Enema | |||||
| Sodium acid phosphate with sodium phosphate (Non-proprietary) | Specialist knowledge/initiation | ||||
| Fleet Ready-to-use (Recordati Pharmaceuticals Ltd) | Specialist knowledge/initiation | ||||
| sodium citrate | Joint formulary choice | ||||
| Oral solution | |||||
| Sodium citrate (Non-proprietary) | |||||
| Enema | |||||
| Micralax Micro-enema (RPH Pharmaceuticals AB) | |||||
| Relaxit (Supra Enterprises Ltd) | |||||
| Irrigation solution | |||||
| Sodium citrate (Non-proprietary) | |||||
| Granules for oral solution | |||||
| Sodium citrate (Non-proprietary) | |||||
| CanesOasis (Bayer Plc) | |||||
| Cystocalm (Galpharm International Ltd) | |||||
| Powder for oral solution | |||||
| Sodium citrate (Non-proprietary) | |||||
| sodium picosulfate | Hospital only | ||||
| Oral solution | |||||
| Sodium picosulfate (Non-proprietary) | Not approved for prescribing | ||||
| Dulco-Lax (Sanofi Consumer Healthcare) | |||||
| sterculia | Not approved for prescribing | ||||
| sterculia with frangula | Not approved for prescribing | ||||
| Gastro-intestinal system / Biliary disorders | |||||
| borneol with camphene, cineole, menthol, menthone and pinene | Not approved for prescribing | ||||
| Gastro-resistant capsule | |||||
| Rowachol (Meadow Laboratories Ltd) | Not approved for prescribing | ||||
| chenodeoxycholic acid | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Oral capsule | |||||
| Chenodeoxycholic acid (Non-proprietary) | |||||
| cholic acid | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Oral capsule | |||||
| Orphacol (Abacus Medicine Pharma Services Ltd) | |||||
| colestyramine | Joint formulary choice | ||||
| Powder for oral suspension | |||||
| Colestyramine (Non-proprietary) | |||||
| Questran (Neon Healthcare Ltd) | |||||
| Questran Light (Neon Healthcare Ltd) | |||||
| maralixibat | |||||
| Oral solution | |||||
| Livmarli (Mirum Pharmaceuticals International BV) | |||||
| obeticholic acid | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA443 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Oral tablet | |||||
| Ocaliva (Advanz Pharma) | |||||
| odevixibat |
NICE HST17 |
||||
| Oral capsule | |||||
| Bylvay (Ipsen Ltd) | |||||
| ursodeoxycholic acid | Specialist knowledge/initiation | ||||
| Oral suspension | |||||
| Ursofalk (Dr. Falk Pharma UK Ltd) | Specialist knowledge/initiation | ||||
| Oral tablet | |||||
| Ursodeoxycholic acid (Non-proprietary) | |||||
| Cholurso (Mayoly UK Ltd) | |||||
| Ursofalk (Dr. Falk Pharma UK Ltd) | |||||
| Ursonorm (PRO.MED.CS Praha a.s.) | |||||
| Oral capsule | |||||
| Ursodeoxycholic acid (Non-proprietary) | |||||
| Ursofalk (Dr. Falk Pharma UK Ltd) | |||||
| Ursonorm (PRO.MED.CS Praha a.s.) | |||||
| Gastro-intestinal system / Hepatic encephalopathy | |||||
| lactulose | Specialist knowledge/initiation | ||||
| Oral solution | |||||
| Lactulose (Non-proprietary) | Specialist knowledge/initiation | ||||
| rifaximin | Specialist knowledge/initiation |
NICE TA337 |
|||
|
Rifaximin not approved for 'small intestinal bacterial overgrowth'
September 2020 - the Joint Prescribing Group (JPG) declined the application for rifaximin to be used for small intestinal bacterial overgrowth. Formulary status - Red (not approved for prescribing) |
|||||
| Oral suspension | |||||
| Rifaximin (Non-proprietary) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Targaxan (Norgine Pharmaceuticals Ltd) | |||||
| Xifaxanta (Norgine Pharmaceuticals Ltd) | |||||
| Gastro-intestinal system / Hepatorenal syndrome | |||||
| terlipressin acetate | |||||
| Solution for injection | |||||
| Terlipressin acetate (Non-proprietary) | |||||
| Gastro-intestinal system / Oesophageal varices | |||||
| carvedilol | |||||
| Oral tablet | |||||
| Carvedilol (Non-proprietary) | |||||
| propranolol hydrochloride | |||||
| Modified-release capsule | |||||
| Bedranol SR (Almus Pharmaceuticals Ltd, Sandoz Ltd) | |||||
| Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
| Half Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
| Oral solution | |||||
| Propranolol hydrochloride (Non-proprietary) | |||||
| Oral tablet | |||||
| Propranolol hydrochloride (Non-proprietary) | |||||
| terlipressin acetate | Hospital only | ||||
| Solution for injection | |||||
| Terlipressin acetate (Non-proprietary) | Hospital only | ||||
| vasopressin | Hospital only | ||||
| Solution for injection | |||||
| Vasopressin (Non-proprietary) | Hospital only | ||||
| Gastro-intestinal system / Obesity | |||||
| liraglutide | Hospital only |
NICE TA664 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
|
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine
This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use. |
|||||
| Solution for injection | |||||
| Saxenda (Novo Nordisk Ltd) | Hospital only | ||||
| Victoza (Novo Nordisk Ltd) | Not approved for prescribing | ||||
| naltrexone with bupropion | Not approved for prescribing |
NICE TA494 |
|||
|
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine
This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use. |
|||||
| Modified-release tablet | |||||
| Mysimba (Orexigen Therapeutics Ireland Ltd) | Not approved for prescribing | ||||
| orlistat | Joint formulary choice | ||||
| Oral capsule | |||||
| Orlistat (Non-proprietary) | |||||
| Alli (Haleon UK Ltd) | |||||
| Orlos (Crescent Pharma Ltd) | |||||
| Xenical (Neon Healthcare Ltd) | |||||
| semaglutide | Hospital only |
NICE TA875 |
|||
| Solution for injection | |||||
| Ozempic (Novo Nordisk Ltd) | Not approved for prescribing | ||||
| Wegovy FlexTouch (Novo Nordisk Ltd) | Hospital only | ||||
| Oral tablet | |||||
| Rybelsus (Novo Nordisk Ltd) | |||||
| setmelanotide |
NICE HST21 NICE HST31 |
||||
| Solution for injection | |||||
| Imcivree (Rhythm Pharmaceuticals UK Ltd) | |||||
| tirzepatide |
NICE TA924 |
||||
| Solution for injection | |||||
| Mounjaro KwikPen (Eli Lilly and Company Ltd) | |||||
| Gastro-intestinal system / Diarrhoea | |||||
| co-phenotrope | Not approved for prescribing | ||||
| Oral tablet | |||||
| Co-phenotrope (Non-proprietary) | |||||
| codeine phosphate | Not approved for prescribing | ||||
| Oral solution | |||||
| Codeine phosphate (Non-proprietary) | Not approved for prescribing | ||||
| Galcodine (Thornton & Ross Ltd) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Codeine phosphate (Non-proprietary) | |||||
| colesevelam hydrochloride | Specialist knowledge/initiation | ||||
|
Joint Prescribing Group's decision
September 2020 - the Joint Prescribing Group (JPG) agreed to approve the addition of colesevelam to the joint formulary for the management of diarrhoea associated with bile acid malabsorption. Product selection Colestyramine light should be selected first line during the shortages of colestyramine. Colesevalam has been added as a formulary option for use in patients who are already taking colestyramine, but are unable to access colestyramine or colestyramine light. The switching between these products is not equivalent and thus GPs needing to make this switch should seek specialist advice from HUHFT gastroenterology service. This can be via the GP email Advice & Guidance service. Newly diagnosed patients with bile acid malabsorption requiring colesevalam should have treatment initiated by a gastroenterologist. Prescribing should be titrated in secondary care until symptom response, following which prescribing can be continued in the community. |
|||||
| Oral tablet | |||||
| Colesevelam hydrochloride (Non-proprietary) | |||||
| Cholestagel (Neon Healthcare Ltd) | |||||
| colestyramine | Joint formulary choice | ||||
| Powder for oral suspension | |||||
| Colestyramine (Non-proprietary) | |||||
| Questran (Neon Healthcare Ltd) | |||||
| Questran Light (Neon Healthcare Ltd) | |||||
| kaolin with morphine | Not approved for prescribing | ||||
| loperamide hydrochloride | Joint formulary choice | ||||
| Orodispersible tablet | |||||
| Imodium (McNeil Products Ltd) | Not approved for prescribing | ||||
| Oral lyophilisate | |||||
| Loperamide hydrochloride (Non-proprietary) | |||||
| Oral tablet | |||||
| Loperamide hydrochloride (Non-proprietary) | |||||
| Norimode (Tillomed Laboratories Ltd) | |||||
| Oral capsule | |||||
| Loperamide hydrochloride (Non-proprietary) | Joint formulary choice | ||||
| loperamide with simeticone | Not approved for prescribing | ||||
| Oral tablet | |||||
| Imodium Plus (McNeil Products Ltd) | |||||
| opium | |||||
| Oral drops | |||||
| Dropizol (Atnahs Pharma UK Ltd) | |||||
| Gastro-intestinal system / Gastro-intestinal smooth muscle spasm | |||||
| alverine citrate | Joint formulary choice | ||||
| Oral capsule | |||||
| Alverine citrate (Non-proprietary) | |||||
| Audmonal (Teva UK Ltd) | |||||
| Spasmonal (Viatris UK Healthcare Ltd) | |||||
| atropine sulfate | Not approved for prescribing | ||||
| Solution for injection | |||||
| Atropine sulfate (Non-proprietary) | |||||
| Eye drops | |||||
| Atropine sulfate (Non-proprietary) | |||||
| dicycloverine hydrochloride | Joint formulary choice | ||||
| Oral solution | |||||
| Dicycloverine hydrochloride (Non-proprietary) | Joint formulary choice | ||||
| Oral tablet | |||||
| Dicycloverine hydrochloride (Non-proprietary) | |||||
| dicycloverine hydrochloride with aluminium hydroxide, magnesium oxide and simeticone | Not approved for prescribing | ||||
| hyoscine butylbromide | Joint formulary choice | ||||
| Solution for injection | |||||
| Hyoscine butylbromide (Non-proprietary) | |||||
| Buscopan (Sanofi Consumer Healthcare) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Oral tablet | |||||
| Hyoscine butylbromide (Non-proprietary) | |||||
| Buscopan (Sanofi Consumer Healthcare) | |||||
| mebeverine hydrochloride | Joint formulary choice | ||||
|
Mebeverine Hydrochloride
Mebeverine oral suspension has NOT been approved for prescribing. |
|||||
| Modified-release capsule | |||||
| Mebeverine hydrochloride (Non-proprietary) | Joint formulary choice | ||||
| Aurobeverine MR (Milpharm Ltd) | Joint formulary choice | ||||
| Colofac MR (Viatris UK Healthcare Ltd) | Joint formulary choice | ||||
| Oral suspension | |||||
| Mebeverine hydrochloride (Non-proprietary) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Mebeverine hydrochloride (Non-proprietary) | |||||
| Colofac (Viatris UK Healthcare Ltd) | |||||
| propantheline bromide | Hospital only | ||||
| Oral tablet | |||||
| Propantheline bromide (Non-proprietary) | |||||
| Pro-Banthine (Kyowa Kirin International UK NewCo Ltd) | |||||
| Gastro-intestinal system / Exocrine pancreatic insufficiency | |||||
| pancreatin | Specialist knowledge/initiation | ||||
| Gastro-resistant capsule | |||||
| Creon (Viatris UK Healthcare Ltd) | Specialist knowledge/initiation | ||||
| Nutrizym (Zentiva Pharma UK Ltd) | Specialist knowledge/initiation | ||||
| Gastro-resistant granules | |||||
| Creon (Viatris UK Healthcare Ltd) | Specialist knowledge/initiation | ||||
| Oral capsule | |||||
| Pancrex (Essential Pharma Ltd) | |||||
| Powder for gastroenteral or oral liquid | |||||
| Pancrex (Essential Pharma Ltd) | |||||
| Gastro-intestinal system / Dyspepsia | |||||
| alginic acid | Joint formulary choice | ||||
| Oral powder | |||||
| Gaviscon Infant (Forum Health Products Ltd) | |||||
| co-magaldrox | Joint formulary choice | ||||
| Oral suspension | |||||
| Mucogel (Rosemont Pharmaceuticals Ltd) | Joint formulary choice | ||||
| co-simalcite | Not approved for prescribing | ||||
| magnesium carbonate | Not approved for prescribing | ||||
| magnesium trisilicate | Not approved for prescribing | ||||
| magnesium trisilicate with magnesium carbonate and sodium bicarbonate | Not approved for prescribing | ||||
| Oral suspension | |||||
| Magnesium trisilicate with magnesium carbonate and sodium bicarbonate (Non-proprietary) | Not approved for prescribing | ||||
| simeticone | Hospital only | ||||
| Oral suspension | |||||
| Infacol (Teva UK Ltd) | Hospital only | ||||
| Oral drops | |||||
| Dentinox Infant (Dendron Brands Ltd) | Not approved for prescribing | ||||
| simeticone with aluminium hydroxide and magnesium hydroxide | Not approved for prescribing | ||||
| Oral suspension | |||||
| Maalox Plus (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
| sodium alginate with potassium bicarbonate | Joint formulary choice | ||||
| Chewable tablet | |||||
| Gaviscon Advance (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
| Oral suspension | |||||
| Acidex Advance (Wockhardt UK Ltd) | Not approved for prescribing | ||||
| Gaviscon Advance (Reckitt Benckiser Healthcare (UK) Ltd) | Joint formulary choice | ||||
| Gastro-intestinal system / Gastric and duodenal ulceration | |||||
| bismuth subsalicylate | |||||
| Chewable tablet | |||||
| Pepto-Bismol (Procter & Gamble (Health & Beauty Care) Ltd) | |||||
| Oral suspension | |||||
| Pepto-Bismol (Procter & Gamble (Health & Beauty Care) Ltd) | |||||
| cimetidine | Not approved for prescribing | ||||
| Oral solution | |||||
| Cimetidine (Non-proprietary) | Not approved for prescribing | ||||
| Tagamet (Rosemont Pharmaceuticals Ltd) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Cimetidine (Non-proprietary) | |||||
| esomeprazole | Joint formulary choice | ||||
|
Injection/infusion formulations
The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing). |
|||||
| Gastro-resistant tablet | |||||
| Esomeprazole (Non-proprietary) | Joint formulary choice | ||||
| Nexium (Grunenthal Ltd, Haleon UK Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Esomeprazole (Non-proprietary) | Joint formulary choice | ||||
| Emozul (Krka UK Ltd) | Joint formulary choice | ||||
| Gastro-resistant granules | |||||
| Esomeprazole (Non-proprietary) | |||||
| Nexium (Grunenthal Ltd) | Joint formulary choice | ||||
| Powder for solution for injection | |||||
| Esomeprazole (Non-proprietary) | Hospital only | ||||
| Nexium (Grunenthal Ltd) | Hospital only | ||||
| famotidine | Not approved for prescribing | ||||
| Oral tablet | |||||
| Famotidine (Non-proprietary) | |||||
| lansoprazole | Joint formulary choice | ||||
| Orodispersible tablet | |||||
| Lansoprazole (Non-proprietary) | Joint formulary choice | ||||
| Zoton FasTab (Pfizer Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Lansoprazole (Non-proprietary) | Joint formulary choice | ||||
| misoprostol | Not approved for prescribing | ||||
| Oral tablet | |||||
| Angusta (Norgine Pharmaceuticals Ltd) | |||||
| Cytotec (Pfizer Ltd) | |||||
| Topogyne (Nordic Pharma Ltd) | |||||
| Vaginal tablet | |||||
| Misoprostol (Non-proprietary) | |||||
| nizatidine | Not approved for prescribing | ||||
| Oral capsule | |||||
| Nizatidine (Non-proprietary) | |||||
| omeprazole | Joint formulary choice | ||||
|
Injection/infusion formulations
The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing). |
|||||
| Gastro-resistant tablet | |||||
| Omeprazole (Non-proprietary) | Joint formulary choice | ||||
| Losec MUPS (Neon Healthcare Ltd) | Joint formulary choice | ||||
| Mezzopram (Sandoz Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Omeprazole (Non-proprietary) | Joint formulary choice | ||||
| Losec (Neon Healthcare Ltd) | Joint formulary choice | ||||
| Oral suspension | |||||
| Omeprazole (Non-proprietary) | |||||
| Oral solution | |||||
| Omeprazole (Non-proprietary) | |||||
| Powder for solution for infusion | |||||
| Omeprazole (Non-proprietary) | |||||
| pantoprazole | Joint formulary choice | ||||
|
Injection/infusion formulations
The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing). |
|||||
| Gastro-resistant tablet | |||||
| Pantoprazole (Non-proprietary) | Joint formulary choice | ||||
| Powder for solution for injection | |||||
| Pantoprazole (Non-proprietary) | Hospital only | ||||
| Protium (Takeda UK Ltd) | Hospital only | ||||
| rabeprazole sodium | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Rabeprazole sodium (Non-proprietary) | Joint formulary choice | ||||
| Pariet (Eisai Ltd) | Not approved for prescribing | ||||
| ranitidine | Joint formulary choice | ||||
|
Injection/infusion formulations
The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing). |
|||||
| sucralfate | Specialist knowledge/initiation | ||||
| Oral suspension | |||||
| Sucralfate (Non-proprietary) | |||||
| Oral tablet | |||||
| Sucralfate (Non-proprietary) | |||||
| Gastro-intestinal system / Gastro-oesophageal reflux disease | |||||
| cimetidine | Not approved for prescribing | ||||
| Oral solution | |||||
| Cimetidine (Non-proprietary) | Not approved for prescribing | ||||
| Tagamet (Rosemont Pharmaceuticals Ltd) | Not approved for prescribing | ||||
| Oral tablet | |||||
| Cimetidine (Non-proprietary) | |||||
| esomeprazole | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Esomeprazole (Non-proprietary) | Joint formulary choice | ||||
| Nexium (Grunenthal Ltd, Haleon UK Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Esomeprazole (Non-proprietary) | Joint formulary choice | ||||
| Emozul (Krka UK Ltd) | Joint formulary choice | ||||
| Gastro-resistant granules | |||||
| Esomeprazole (Non-proprietary) | |||||
| Nexium (Grunenthal Ltd) | Joint formulary choice | ||||
| Powder for solution for injection | |||||
| Esomeprazole (Non-proprietary) | Hospital only | ||||
| Nexium (Grunenthal Ltd) | Hospital only | ||||
| famotidine | Not approved for prescribing | ||||
| Oral tablet | |||||
| Famotidine (Non-proprietary) | |||||
| lansoprazole | Joint formulary choice | ||||
| Orodispersible tablet | |||||
| Lansoprazole (Non-proprietary) | Joint formulary choice | ||||
| Zoton FasTab (Pfizer Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Lansoprazole (Non-proprietary) | Joint formulary choice | ||||
| nizatidine | Not approved for prescribing | ||||
| Oral capsule | |||||
| Nizatidine (Non-proprietary) | |||||
| omeprazole | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Omeprazole (Non-proprietary) | Joint formulary choice | ||||
| Losec MUPS (Neon Healthcare Ltd) | Joint formulary choice | ||||
| Mezzopram (Sandoz Ltd) | Joint formulary choice | ||||
| Gastro-resistant capsule | |||||
| Omeprazole (Non-proprietary) | Joint formulary choice | ||||
| Losec (Neon Healthcare Ltd) | Joint formulary choice | ||||
| Oral suspension | |||||
| Omeprazole (Non-proprietary) | |||||
| Oral solution | |||||
| Omeprazole (Non-proprietary) | |||||
| Powder for solution for infusion | |||||
| Omeprazole (Non-proprietary) | |||||
| pantoprazole | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Pantoprazole (Non-proprietary) | Joint formulary choice | ||||
| Powder for solution for injection | |||||
| Pantoprazole (Non-proprietary) | Hospital only | ||||
| Protium (Takeda UK Ltd) | Hospital only | ||||
| rabeprazole sodium | Joint formulary choice | ||||
| Gastro-resistant tablet | |||||
| Rabeprazole sodium (Non-proprietary) | Joint formulary choice | ||||
| Pariet (Eisai Ltd) | Not approved for prescribing | ||||
| sodium alginate with calcium carbonate and sodium bicarbonate | Joint formulary choice | ||||
| Oral suspension | |||||
| Sodium alginate with calcium carbonate and sodium bicarbonate (Non-proprietary) | Joint formulary choice | ||||
| Acidex (Pinewood Healthcare) | Not approved for prescribing | ||||
| Gaviscon (Reckitt Benckiser Healthcare (UK) Ltd) | Joint formulary choice | ||||
| Gaviscon Liquid Relief (Reckitt Benckiser Healthcare (UK) Ltd) | Joint formulary choice | ||||
| Peptac (Teva UK Ltd) | Joint formulary choice | ||||
| Rennie (Bayer Plc) | |||||
| Gastro-intestinal system / Helicobacter pylori infection | |||||
| urea (13C) | |||||
| Oral tablet | |||||
| diabact UBT (Mayoly UK Ltd) | |||||
| Powder for oral solution | |||||
| Urea (13C) (Non-proprietary) | |||||